Health Canada, Canada’s governmental health agency, announced that there is now an option for all biological and pharmaceutical new drug submissions to request aligned regulatory reviews between Health Canada and health technology assessment (HTA) organizations.
Health Canada (HC), Canada’s governmental health agency, announced that there is now an option for all biological and pharmaceutical new drug submissions to request aligned regulatory reviews between HC and health technology assessment (HTA) organizations. The HTAs that are collaborating on the aligned review process are the Canadian Agency for Drugs and Technologies in Health (CADTH) and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS).
The HC notice applies to biosimilars, supplemental new drug submissions for new indications when the sponsor intends to seek a coverage recommendation from HTAs on a pre-Notice of Compliance (NOC) basis. The HC policy, effective immediately, formalizes the timelines, process, and considerations for sponsors with qualifying drug submissions and applies to drug sponsors who are “interested in taking part in aligned reviews between HC and HTAs.” The new joint process furthers efforts to reduce the time between market authorization and reimbursement recommendations for public drug plans in order to support affordability, accessibility, and appropriate use of prescription drugs in Canada.
Sponsors of qualifying submissions will be able to opt in to an aligned review pathway at any stage of the review process by completing the template authorizing, sharing of information, and submitting it to HC. HC encourages sponsors to opt in as early as possible in the review process, however. Sponsors must also comply with the advance notice requirement of HTAs.
Sponsors can also use the principles, which HC will apply to all aligned reviews, as a guide when developing applications, including limitations on the sharing of confidential information, independent decision making, and transparency. These principles include:
The initiative’s key benefits include reducing delays between HC’s approval of a drug and the recommendations that CADTH and INESSS issue to advise public drug plans about how drugs should be reimbursed, and improving communication between the organizations and allowing for real-time discussions that can help reduce duplication.
HC hopes the new initiative will further the commonly held goal of helping ensure that all Canadians have access to effective therapies that bring value to patients and the health system. Greater collaboration can help close gaps, reduce delays, and enhance the management of pharmaceuticals in Canada.
In the coming months HC, CADTH, and INESSS will release a webinar to provide interested parties with more information about the process.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.